Recurrence from the Spinal Region of the Patient Whose Treatment Was Completed with Liver and Lung Cystic Echinococcosis: A Rare Pediatric Case of Spinal Cystic Echinococcosis.

Cystic echinococcosis is a parasitic disease caused by the Echinococcus tapeworm. The disease can often affect organs such as the liver and lungs, muscles, bones, kidneys, brain, and spleen. Spinal cystic echinococcosis has been reported very rarely in the literature.

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for ≥3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved.

[Protection of babies born to HBsAg(+) mothers].

Babies of 17 HBsAg positive mothers were passively and actively immunized with HBIG and HBV vaccine. Seven infants born from HBsAg (+) mothers were not immunized with their families decisions and used as control group. 24 infants were followed for 12-18 months.